Volume 8, Issue 4 (7-2010)                   IJRM 2010, 8(4): 161-166 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Agha Hosseini M, Aleyasin A, Mahdavi A, Mokhtar S, Safdarian L, Fallahi P. Relationship between anti-mullerian hormone and assisted reproductive technique outcome in patients with polycystic ovary syndrome. IJRM. 2010; 8 (4) :161-166
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-192-en.html
1- Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran , atossa_mahdavi@yahoo.com
Abstract:   (1346 Views)
Background: Anti-mullerian hormone (AMH) levels may represent the ovarian follicular pool and could be a useful marker of ovarian reserve. The clinical application of AMH measurement has been proposed in the prediction of quantitative and qualitative aspects in assisted reproductive technologies. Objective: This study aimed to assess the relationship between the serum levels of AMH and results of assisted reproductive technique (ART) outcome in polycystic ovary syndrome (PCOS) patients versus control group.
Materials and Methods: This cohort study was conducted on 61 (PCOS) patients and 28 patients without PCOS (controls) candidates for assisted reproductive technique. Serum levels of AMH were measured on the 3rd day of menstrual cycle and all the patients underwent controlled ovarian hyper stimulation and ART. The relationship between AMH serum level with retrieved oocytes, mature oocytes and pregnancy rate were assessed.
Results: There was significant correlation between the AMH level with number of total retrieved oocytes and mature oocytes in patients with PCOS and controls (p=0.001). In PCOS and control groups AMH level in pregnant patients was higher, but it was not statistically significant (p=0.65, p=0.46, respectively). The major outcome of the study (pregnancy) did not differ significantly between two groups.
Conclusion: This study revealed that AMH level was higher in pregnant patients undergoing ART; but AMH may not be an accurate predictor for pregnancy in PCOS patients.
Full-Text [PDF 158 kb]   (213 Downloads) |   |   Full-Text (HTML)  (92 Views)  
Type of Study: Original Article |

References
1. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al. Circulating basal anti-Mullerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009; 92: 1586-1593. [DOI:10.1016/j.fertnstert.2008.08.127]
2. Pe-arrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 2005; 20; 915-922. [DOI:10.1093/humrep/deh718]
3. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. Hum Reprod Update 2001; 7; 581-590. [DOI:10.1093/humupd/7.6.581]
4. Gruijters MJ, Visser JA, Durlinger AL, Themmen AP. Anti- Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol 2003; 15; 211: 85-90. [DOI:10.1016/j.mce.2003.09.024]
5. Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002; 17: 3065-3071. [DOI:10.1093/humrep/17.12.3065]
6. Van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, et al. Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004; 11: 601-606. [DOI:10.1097/01.GME.0000123642.76105.6E]
7. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Carducci Artenisio A, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16: 113-130. [DOI:10.1093/humupd/dmp036]
8. Chu MC, Carmina E, Wang J, Lobo RA. Mullerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B. Fertil Steril 2005; 84: 1685-1688. [DOI:10.1016/j.fertnstert.2005.06.026]
9. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005; 20: 1820-1826. [DOI:10.1093/humrep/deh850]
10. Wang JG, Nakhuda GS, Guarnaccia MM, Sauer MV, Lobo RA. Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196: e1-5. [DOI:10.1016/j.ajog.2006.07.046]
11. Laas A. Assessment of ovarian reserve,is there a role for ovarian biopsy? Hum Reprod 2001;16,1055-1057. [DOI:10.1093/humrep/16.6.1055]
12. Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm). J Assist Reprod Genet 2009; 26:319-325. [DOI:10.1007/s10815-009-9319-5]
13. Desforges-Bullet V, Gallo C, Lefebvre C, Pigny P, Dewailly D, Catteau-Jonard S. Increased anti-mullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril 2009; 94: 198-204. [DOI:10.1016/j.fertnstert.2009.03.004]
14. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 2004; 82:1323-1329. [DOI:10.1016/j.fertnstert.2004.03.061]
15. Barriere P, Freour T, Mirallie S, Jean M, Bach-Ngohou K, Masson D. Anti-mullerian hormone (AMH): Proposition of a cut-off in assisted reproductive therapy (ART) for a promising new marker (measured with Beckman Coulter ELISA). Fertil Steril 2006; 86: S289. [DOI:10.1016/j.fertnstert.2006.07.773]
16. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006; 85:592-596. [DOI:10.1016/j.fertnstert.2005.09.019]
17. Penarrubia J, Fabregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 2005; 20: 915-922. [DOI:10.1093/humrep/deh718]
18. Sills E, Alper M, Walsh A. Ovarian reserve screening in infertility: Practical applications and theoretical directions for research. Eur J Obstet Gynecol Reprod Biol 2009; 146: 30-36. [DOI:10.1016/j.ejogrb.2009.05.008]

Send email to the article author


© 2021 CC BY-NC 4.0 | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb